Amynah A Pradhan1, Monique L Smith, Jekaterina Zyuzin, Andrew Charles. 1. Semel Institute for Neuropsychiatry & Human Behavior, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Headache Research and Treatment Program, Department of Neurology David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; Shirley and Stefan Hatos Center for Neuropharmacology, UCLA, Los Angeles, CA, USA; Department of Psychiatry, University of Illinois at Chicago (UIC), Chicago, IL, USA.
Abstract
BACKGROUND AND PURPOSE: Migraine is an extraordinarily common brain disorder for which treatment options continue to be limited. Agonists that activate the δ-opioid receptor may be promising for the treatment of migraine as they are highly effective for the treatment of chronic rather than acute pain, do not induce hyperalgesia, have low abuse potential and have anxiolytic and antidepressant properties. The aim of this study was to investigate the therapeutic potential of δ-opioid receptor agonists for migraine by characterizing their effects in mouse migraine models. EXPERIMENTAL APPROACH: Mechanical hypersensitivity was assessed in mice treated with acute and chronic doses of nitroglycerin (NTG), a known human migraine trigger. Conditioned place aversion to NTG was also measured as a model of migraine-associated negative affect. In addition, we assessed evoked cortical spreading depression (CSD), an established model of migraine aura, in a thinned skull preparation. KEY RESULTS: NTG evoked acute and chronic mechanical and thermal hyperalgesia in mice, as well as conditioned place aversion. Three different δ-opioid receptor agonists, SNC80, ARM390 and JNJ20788560, significantly reduced NTG-evoked hyperalgesia. SNC80 also abolished NTG-induced conditioned place aversion, suggesting that δ-opioid receptor activation may also alleviate the negative emotional state associated with migraine. We also found that SNC80 significantly attenuated CSD, a model that is considered predictive of migraine preventive therapies. CONCLUSIONS AND IMPLICATIONS: These data show that δ-opioid receptor agonists modulate multiple basic mechanisms associated with migraine, indicating that δ-opioid receptors are a promising therapeutic target for this disorder.
BACKGROUND AND PURPOSE:Migraine is an extraordinarily common brain disorder for which treatment options continue to be limited. Agonists that activate the δ-opioid receptor may be promising for the treatment of migraine as they are highly effective for the treatment of chronic rather than acute pain, do not induce hyperalgesia, have low abuse potential and have anxiolytic and antidepressant properties. The aim of this study was to investigate the therapeutic potential of δ-opioid receptor agonists for migraine by characterizing their effects in mousemigraine models. EXPERIMENTAL APPROACH: Mechanical hypersensitivity was assessed in mice treated with acute and chronic doses of nitroglycerin (NTG), a known humanmigraine trigger. Conditioned place aversion to NTG was also measured as a model of migraine-associated negative affect. In addition, we assessed evoked cortical spreading depression (CSD), an established model of migraine aura, in a thinned skull preparation. KEY RESULTS:NTG evoked acute and chronic mechanical and thermal hyperalgesia in mice, as well as conditioned place aversion. Three different δ-opioid receptor agonists, SNC80, ARM390 and JNJ20788560, significantly reduced NTG-evoked hyperalgesia. SNC80 also abolished NTG-induced conditioned place aversion, suggesting that δ-opioid receptor activation may also alleviate the negative emotional state associated with migraine. We also found that SNC80 significantly attenuated CSD, a model that is considered predictive of migraine preventive therapies. CONCLUSIONS AND IMPLICATIONS: These data show that δ-opioid receptor agonists modulate multiple basic mechanisms associated with migraine, indicating that δ-opioid receptors are a promising therapeutic target for this disorder.
Authors: A C Hutchinson; G R Simpson; J F Randall; X Zhang; S N Calderon; K C Rice; A L Riley Journal: Pharmacol Biochem Behav Date: 2000-08 Impact factor: 3.533
Authors: Claire Gaveriaux-Ruff; Chihiro Nozaki; Xavier Nadal; Xavier C Hever; Raphael Weibel; Audrey Matifas; David Reiss; Dominique Filliol; Mohammed A Nassar; John N Wood; Rafael Maldonado; Brigitte L Kieffer Journal: Pain Date: 2011-02-03 Impact factor: 6.961
Authors: E A Bates; T Nikai; K C Brennan; Y-H Fu; A C Charles; A I Basbaum; L J Ptácek; A H Ahn Journal: Cephalalgia Date: 2010-02 Impact factor: 6.292
Authors: Neil T Burford; Kathryn E Livingston; Meritxell Canals; Molly R Ryan; Lauren M L Budenholzer; Ying Han; Yi Shang; John J Herbst; Jonathan O'Connell; Martyn Banks; Litao Zhang; Marta Filizola; Daniel L Bassoni; Tom S Wehrman; Arthur Christopoulos; John R Traynor; Samuel W Gerritz; Andrew Alt Journal: J Med Chem Date: 2015-05-07 Impact factor: 7.446
Authors: Aurélien Quenault; Sara Martinez de Lizarrondo; Olivier Etard; Maxime Gauberti; Cyrille Orset; Benoît Haelewyn; Helen C Segal; Peter M Rothwell; Denis Vivien; Emmanuel Touzé; Carine Ali Journal: Brain Date: 2016-11-08 Impact factor: 13.501
Authors: Isaac J Dripps; Ruizhuo Chen; Amanda M Shafer; Kathryn E Livingston; Alexander Disney; Stephen M Husbands; John R Traynor; Kenner C Rice; Emily M Jutkiewicz Journal: J Pharmacol Exp Ther Date: 2020-05-28 Impact factor: 4.030
Authors: Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz Journal: Psychopharmacology (Berl) Date: 2016-09-13 Impact factor: 4.530